Yes, VZV antibody-positive patients on ofatumumab should still receive Shingrix
Having VZV antibodies does not change the recommendation—patients receiving ofatumumab should receive the recombinant zoster vaccine (Shingrix) regardless of their VZV serostatus. The presence of antibodies indicates prior varicella exposure, which actually makes these patients eligible and appropriate candidates for herpes zoster vaccination, as they are at risk for viral reactivation.
Why VZV Seropositivity Supports Vaccination
The recombinant zoster vaccine is specifically designed to prevent herpes zoster (shingles), which results from reactivation of latent VZV—not primary infection. Over 95% of adults aged ≥50 years are VZV seropositive, and this is precisely the population for whom Shingrix is indicated 1. The vaccine works by boosting cell-mediated immunity against VZV glycoprotein E to prevent reactivation from latency in sensory ganglia.
Ofatumumab and Herpes Zoster Risk
Patients receiving ofatumumab (an anti-CD20 monoclonal antibody) face substantially elevated herpes zoster risk due to B-cell depletion and immunosuppression. Multiple myeloma network guidelines specifically recommend recombinant zoster vaccine for patients on immunosuppressive therapies, including anti-CD20 antibodies 2. The NCCN guidelines state that RZV is recommended for adults ≥18 years who are at increased risk for herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy 3.
Vaccination Strategy for Ofatumumab Patients
Administer two doses of Shingrix 1-2 months apart (the accelerated schedule approved for immunocompromised patients), ideally:
- Before starting ofatumumab if possible, as immune responses are optimal prior to B-cell depletion 4
- If already on therapy, vaccinate anyway—studies show patients on anti-CD20 therapies can mount T-cell responses to RZV even with impaired humoral immunity 5, 6
- Time vaccination at least 2 weeks before the next ofatumumab dose when feasible to maximize response 4
Evidence in Immunocompromised Populations
The recombinant zoster vaccine has demonstrated robust efficacy in immunocompromised patients:
- 80.4% of patients with hematologic malignancies on immunosuppressive therapy mounted vaccine responses 6
- Protection persisted through 13 months post-vaccination even in heavily immunosuppressed populations 6
- The vaccine is non-replicating (not live), making it safe in immunocompromised patients 7, 8—unlike the older live-attenuated zoster vaccine which is contraindicated
Safety Considerations
While Shingrix is more reactogenic than placebo (injection-site pain in ~80%, fatigue in ~58%), these reactions are typically mild-to-moderate and transient 9. Serious adverse events occur at similar rates to placebo 6. The FDA label explicitly states the vaccine is indicated for adults ≥18 years who are or will be immunocompromised 9.
Common pitfall: Do not confuse VZV seropositivity with contraindication. The opposite is true—seronegative patients (no prior varicella) would need varicella vaccination first, not zoster vaccination. VZV antibodies confirm prior exposure and latent virus, making herpes zoster prevention relevant.
Bottom line: Proceed with the two-dose Shingrix series regardless of positive VZV antibodies. The seropositivity confirms the patient has latent virus that could reactivate, and ofatumumab significantly increases this risk. The vaccine's safety profile in immunocompromised patients is well-established 3, 10.